lipegfilgrastim
XM22-ONC-305
Phase 3 small_molecule completed
Quick answer
lipegfilgrastim for Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia is a Phase 3 program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed